| Survival of aging CD264(+) and CD264(-) populations of human bone marrow mesenchymal stem cells is independent of colony-forming efficiency. | Survival of aging CD264(+) and CD264(-) populations of human bone marrow mesenchymal stem cells is independent of colony-forming efficiency.
Madsen SD, Jones SH, Tucker HA, Giler MK, Muller DC, Discher CT, Russell KC, Dobek GL, Sammarco MC, Bunnell BA, O'Connor KC., Free PMC Article | 02/6/2021 |
| data suggest that the determination of intracellular co-expression patterns of TRAIL-R1, TRAIL-R2, and TRAIL-R4 provides an innovative and robust method for risk stratification in breast cancer patients beyond conventional prognostic markers. | Heterogeneous intracellular TRAIL-receptor distribution predicts poor outcome in breast cancer patients.
Heilmann T, Vondung F, Borzikowsky C, Szymczak S, Krüger S, Alkatout I, Wenners A, Bauer M, Klapper W, Röcken C, Maass N, von Karstedt S, Schem C, Trauzold A. | 06/20/2020 |
| The high-dose hook effect was apparent during ELISA testing of uDcR2 in chronic kidney disease (CKD) patients, yet dilution of the urine samples neutralized this effect. However, the use of a four-fold dilution of urine for uDcR2/cre testing may eliminate the high-dose hook effect and make it possible to effectively monitor the severity of TII in CKD patients. | High-dose HOOK effect in urinary DcR2 assay in patients with chronic kidney disease.
Chen J, Chen KH, Wang LM, Zhang WW, Feng L, Dai HZ, He YN. | 09/1/2018 |
| results suggest that CD264 is a surface marker of cellular age for bone marrow-derived mesenchymal stem cells. | Decoy TRAIL receptor CD264: a cell surface marker of cellular aging for human bone marrow-derived mesenchymal stem cells.
Madsen SD, Russell KC, Tucker HA, Glowacki J, Bunnell BA, O'Connor KC., Free PMC Article | 06/30/2018 |
| Urinary DcR2 could potentially serve as a novel biomarker for tubulointerstitial injury and may reflect senescence of renal proximal tubular cells in diabetic nephropathy. | Urinary DcR2 is a novel biomarker for tubulointerstitial injury in patients with diabetic nephropathy.
Chen J, Zhang WW, Chen KH, Lin LR, Dai HZ, Li KL, Zhang JG, Zheng LQ, Fu BQ, He YN. | 09/23/2017 |
| Results identified epigenetic inactivation of TNFRSF10C and TNFRSF10D in majority of cervical cancer cases. | Epigenetic inactivation of TRAIL decoy receptors at 8p12-21.3 commonly deleted region confers sensitivity to Apo2L/trail-Cisplatin combination therapy in cervical cancer.
Narayan G, Xie D, Ishdorj G, Scotto L, Mansukhani M, Pothuri B, Wright JD, Kaufmann AM, Schneider A, Arias-Pulido H, Murty VV. | 10/22/2016 |
| DcRs regulate TRAIL sensitivity at a supracellular level | Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity.
O'Leary L, van der Sloot AM, Reis CR, Deegan S, Ryan AE, Dhami SP, Murillo LS, Cool RH, Correa de Sampaio P, Thompson K, Murphy G, Quax WJ, Serrano L, Samali A, Szegezdi E. | 07/30/2016 |
| membrane expression more common in endometrioid endometrial cancer than in normal endometrium | Membrane expression of trail receptors DcR1 and DcR2 in the normal endometrium, endometrial atypical hyperplasia and endometrioid endometrial cancer.
Gottwald L, Pasz-Walczak G, Piekarski J, Szwalski J, Kubiak R, Spych M, Suzin J, Tyliński W, Sęk P, Jeziorski A. | 04/18/2015 |
| This study identified TNFRSF10D DNA methylation status as an independent prognostic biomarker for relapse-free survival and overall mortality in non-metastatic melanoma patients. | Association of TNFRSF10D DNA-methylation with the survival of melanoma patients.
Ratzinger G, Mitteregger S, Wolf B, Berger R, Zelger B, Weinlich G, Fritsch P, Goebel G, Fiegl H., Free PMC Article | 04/4/2015 |
| The membrane expression of the TRAIL receptors DR4, DR5, DcR1 and DcR2 is greater in normal endometrium than endometrioid adenocarcinoma (EAC). The level of the receptors in EAC is not dependent on grading and staging and does not predict survival. | Membrane expression of TRAIL receptors DR4, DR5, DcR1 and DcR2 in the normal endometrium, atypical endometrial hyperplasia and endometrioid adenocarcinoma: a tissue microarray study.
Gottwald L, Piekarski J, Kubiak R, Szwalski J, Pasz-Walczak G, Sęk P, Spych M, Suzin J, Tyliński W, Jeziorski A., Free PMC Article | 05/24/2014 |
| the results presented here claim for a relevant impact of aberrant methylation of decoy receptors in melanoma and allow to understand how the silencing of DcR1 and DcR2 is related to melanomagenesis. | Impact of DNA methyltransferases on the epigenetic regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in malignant melanoma.
Venza M, Visalli M, Catalano T, Fortunato C, Oteri R, Teti D, Venza I. | 04/5/2014 |
| transcript levels of UCHL1, COL1A2, THBS1 and TNFRSF10D were inversely correlated with promoter methylation | Cross-platform array screening identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as genes frequently silenced by methylation in melanoma.
Bonazzi VF, Nancarrow DJ, Stark MS, Moser RJ, Boyle GM, Aoude LG, Schmidt C, Hayward NK., Free PMC Article | 02/25/2012 |
| TRAIL receptor-4 expression profiles on T cells might be important in revelation of rheumatoid arthritis pathogenesis. | TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis.
Bisgin A, Terzioglu E, Aydin C, Yoldas B, Yazisiz V, Balci N, Bagci H, Gorczynski RM, Akdis CA, Sanlioglu S., Free PMC Article | 06/18/2011 |
| ANT2 shRNA treatment sensitized MCF7, T47 D, and BT474 cells to TRAIL-induced apoptosis by up-regulating the expression of TRAIL death receptors 4 and 5 (DR4 and DR5) and down-regulating the TRAIL decoy receptor 2 (DcR2). | Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression.
Jang JY, Jeon YK, Choi Y, Kim CW., Free PMC Article | 01/22/2011 |
| Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) | MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer.
Zhang X, Yang H, Lee JJ, Kim E, Lippman SM, Khuri FR, Spitz MR, Lotan R, Hong WK, Wu X., Free PMC Article | 12/5/2010 |
| Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) | Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
Bailey SD, Xie C, Do R, Montpetit A, Diaz R, Mohan V, Keavney B, Yusuf S, Gerstein HC, Engert JC, Anand S, DREAM investigators., Free PMC Article | 09/15/2010 |
| these results demonstrated that hypoxia-inducible factor 1alpha played a crucial role in regulating the transcription of DcR2. | Hypoxia-induced decoy receptor 2 gene expression is regulated via a hypoxia-inducible factor 1alpha-mediated mechanism.
Pei GT, Wu CW, Lin WW. | 03/15/2010 |
| Higher levels of TRAIL and the TRAIL decoy receptor, TRAIL R4, were expressed by leukocytes in inflamed human periodontal tissues. | Inhibition of apoptosis in periodontitis.
Lucas H, Bartold PM, Dharmapatni AA, Holding CA, Haynes DR. | 01/21/2010 |
| Results indicate that disc cells, after herniation, undergo apoptotic cell death via the DR5/TRAIL pathway. | DR5 and DcR2 are expressed in human lumbar intervertebral discs.
Chen B, Ma B, Yang S, Xing X, Gu R, Hu Y. | 01/21/2010 |
| High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients. | High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients.
Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Ozdogan M, Suleymanlar I, Balci MK, Griffith TS, Sanlioglu S. | 01/21/2010 |
| DCR2-methylated patients showed significantly poorer 5-year event-free survival in the whole neuroblastoma group (43% | Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma.
Yagyu S, Gotoh T, Iehara T, Miyachi M, Katsumi Y, Tsubai-Shimizu S, Kikuchi K, Tamura S, Tsuchiya K, Imamura T, Misawa-Furihata A, Sugimoto T, Sawada T, Hosoi H. | 01/21/2010 |
| These data strongly support a recent proposal that a segment at 8p21.3 contains crucial prostate cancer tumor suppressors. | Protein phosphatase and TRAIL receptor genes as new candidate tumor genes on chromosome 8p in prostate cancer.
Hornstein M, Hoffmann MJ, Alexa A, Yamanaka M, Müller M, Jung V, Rahnenführer J, Schulz WA. | 01/21/2010 |
| Observational study of gene-disease association. (HuGE Navigator) | See all PubMed (6) articlesCommon single nucleotide polymorphisms in immunoregulatory genes and multiple myeloma risk among women in Connecticut.
Lee KM, Baris D, Zhang Y, Hosgood HD 3rd, Menashe I, Yeager M, Zahm SH, Wang SS, Purdue MP, Chanock S, Zheng T, Rothman N, Lan Q. New genetic associations detected in a host response study to hepatitis B vaccine.
Davila S, Froeling FE, Tan A, Bonnard C, Boland GJ, Snippe H, Hibberd ML, Seielstad M. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.
Talmud PJ, Drenos F, Shah S, Shah T, Palmen J, Verzilli C, Gaunt TR, Pallas J, Lovering R, Li K, Casas JP, Sofat R, Kumari M, Rodriguez S, Johnson T, Newhouse SJ, Dominiczak A, Samani NJ, Caulfield M, Sever P, Stanton A, Shields DC, Padmanabhan S, Melander O, Hastie C, Delles C, Ebrahim S, Marmot MG, Smith GD, Lawlor DA, Munroe PB, Day IN, Kivimaki M, Whittaker J, Humphries SE, Hingorani AD, ASCOT investigators, NORDIL investigators, BRIGHT Consortium. Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.
Hosgood HD 3rd, Zhang L, Shen M, Berndt SI, Vermeulen R, Li G, Yin S, Yeager M, Yuenger J, Rothman N, Chanock S, Smith M, Lan Q. Common genetic variants in candidate genes and risk of familial lymphoid malignancies.
Liang XS, Caporaso N, McMaster ML, Ng D, Landgren O, Yeager M, Chanock S, Goldin LR. Polymorphisms in TRAIL receptor genes and risk of breast cancer in Spanish women.
Martinez-Ferrandis JI, Rodríguez-López R, Milne RL, González E, Cebolla E, Chirivella I, Zamora P, Arias JI, Palacios S, Cervantes A, Díez O, Benitez J, Armengod ME. | 03/13/2008 |
| Observational study of genotype prevalence. (HuGE Navigator) | Identification of single nucleotide polymorphisms in the tumor necrosis factor (TNF) and TNF receptor superfamily in the Korean population.
Cho SM, Kim J, Ryu HJ, Kim JJ, Kim HH, Park JH, Kim HT, Kim KH, Cho HY, Oh B, Park C, Kimm K, Jo I, Lee JE, Shin HD, Lee JK. | 03/13/2008 |
| Resistance to TRAIL-induced apoptosis in acute myeloid leukemia cells is associated with expression of TRAIL-R4. | TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.
Riccioni R, Pasquini L, Mariani G, Saulle E, Rossini A, Diverio D, Pelosi E, Vitale A, Chierichini A, Cedrone M, Foà R, Lo Coco F, Peschle C, Testa U. | 01/21/2010 |